Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I—methods

Urology ◽  
2000 ◽  
Vol 56 (6) ◽  
pp. 972-980 ◽  
Author(s):  
Stacey J Ackerman ◽  
Alison L Rein ◽  
Michael Blute ◽  
Kathleen Beusterien ◽  
Erin M Sullivan ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia

Cost-Effectiveness of Tamsulosin, Doxazosin, and Terazosin in the Treatment of Benign Prostatic Hyperplasia

2004 ◽  
Vol 10 (5) ◽  
pp. 412-422 ◽  
Author(s):  
Robert L. Ohsfeldt ◽  
Karl J. Kreder ◽  
Robert W. Klein ◽  
Elizabeth A. Chrischilles
Keyword(s):  
Cost Effectiveness ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia

scholarly journals Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia

2021 ◽  
Vol 8 (1) ◽  
pp. 42-50
Author(s):  
Bilal Chughtai ◽  
Sirikan Rojanasarot ◽  
Kurt Neeser ◽  
Dmitry Gultyaev ◽  
Stacey L. Amorosi ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Benign Prostatic Hyperplasia ◽  
Minimally Invasive ◽  
Budget Impact ◽  
Prostatic Hyperplasia ◽  
Minimally Invasive Surgical ◽  
Medication Costs ◽  
Life Years ◽  
Surgical Treatments ◽  
The Cost

Background: Benign prostatic hyperplasia (BPH) is one of the most prevalent and costly chronic conditions among middle-aged and elderly men. Prostatic urethral lift (PUL) and convective water vapor thermal therapy (WVTT) are emerging minimally invasive surgical treatments as an alternative to traditional treatment options for men with moderate-to-severe BPH. This study evaluated the cost-effectiveness and budget impact of PUL and WVTT for men with BPH using long-term clinical outcomes. Methods: The cost-effectiveness and budget impact models were developed from a US Medicare perspective over a 4-year time horizon. The models were populated with males with a mean age of 63 and an average International Prostate Symptom Score (IPSS) of 22. Clinical inputs were extracted from the LIFT and Rezum II randomized controlled trials at 4 years. Utility values were assigned using IPSS and BPH severity levels. Procedural, adverse event, retreatment, follow-up, and medication costs were based on 2019 Medicare payment rates and Medicare Part D drug spending. One-way and probabilistic sensitivity analyses (PSAs) were performed. Results: At 4 years, PUL was associated with greater retreatment rates (24.6% vs 10.9%), lower quality-adjusted life-years (QALYs) (3.490 vs 3.548) and higher total costs (US$7393 vs US$2233) compared with WVTT, making WVTT the more effective and less costly treatment strategy. The 70% total cost difference of PUL and WVTT was predominantly driven by higher PUL procedural (US$5617 vs US$1689) and retreatment (US$976 vs US$257) costs. The PSA demonstrated that relative to PUL, WVTT yielded higher QALYs and lower costs 99% and 100% of the time, respectively. Conclusions: Compared to PUL, WVTT was a cost-effective and cost-saving treatment of moderate-to-severe BPH. These findings provide evidence for clinicians, payers, and health policy makers to help further define the role of minimally invasive surgical treatments for BPH.

The Long-Term Cost Effectiveness of Treatments for Benign Prostatic Hyperplasia

2006 ◽  
Vol 24 (2) ◽  
pp. 171-191 ◽  
Author(s):  
Rachael L DiSantostefano ◽  
Andrea K Biddle ◽  
John P Lavelle
Keyword(s):  
Cost Effectiveness ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia

scholarly journals Comparison of Safety, Efficacy and Cost Effectiveness of Photoselective Vaporization with Bipolar Vaporization of Prostate in Benign Prostatic Hyperplasia

2017 ◽  
Vol 11 (2) ◽  
pp. 103-109 ◽  
Author(s):  
Priyanka Rai ◽  
Alok Srivastava ◽  
Ishwar R. Dhayal ◽  
Sanjeet Singh
Keyword(s):  
Quality Of Life ◽  
Cost Effectiveness ◽  
Benign Prostatic Hyperplasia ◽  
Blood Transfusion ◽  
Maximum Flow ◽  
Prostatic Hyperplasia ◽  
International Prostatic Symptom Score ◽  
Photoselective Vaporization

Objectives: To compare bipolar vaporization of prostate (BPVP) with photoselective vaporization (PVP) of prostate in the surgical management of benign prostatic hyperplasia in terms of safety, efficacy and cost effectiveness. Methods: Data was analyzed retrospectively for patients who underwent either PVP or BPVP between August 2012 to July 2014 for prostate size ≤ 80 ml. Preoperative and postoperative period values along with details like operative time, blood loss, hospitalization days, catheter removal time, blood transfusion and etc., were noted down. International prostatic symptom score, quality of life scores, post void residue, and maximum flow rate were recorded preoperatively and postoperatively at each follow-up visit. Follow-up was performed at 1, 3, 6 ,12 and 18 months. Results: Similar preoperative characteristics were observed in all the study arms. Hemoglobin drop, transfusion rate, catheter time and hospital days were similar in both the groups. The follow-up data indicates sustainable significant improvement in international prostatic symptom score, quality of life, post void residue and maximum flow rate in both the groups. As expected the cost of the procedure was significantly more in PVP group as compared to BPVP group (p < 0.01). Neither group had severe perioperative complications and no blood transfusion was required in both the groups. Conclusion: Both PVP and BPVP were safe and effective alternatives in men requiring surgery for benign prostatic hyperplasia including patients who were on anticoagulants. Additionally, BPVP has the advantage of being significantly cheaper and therefore it can be more useful in developing countries.

Sign in / Sign up

Export Citation Format

Share Document